8 - 9 September 2021
9th Annual Biologics World Taiwan 2021
Virtual Conference
Join the 9th Annual Biologics World Taiwan 2021!
200+
High Profile Attendees
30+
Industry Experts & Speakers
20+
Hours of Networking
10+
Case Studies
The Concept
While China, India, and Korea are leading the pack in the Asian region for biologics, Taiwan has also been stepping up its efforts to boost its biologics sector and capture a share of the global market. The 2009 national plan for biotech development helped kick-start the sector, which has since doubled in revenue size to reach NT$ 118.6bn (US$3.8bn) in 2019. The main focus is on the development of new drugs and biologics.
Strong government commitment has helped drive the expansion of the biotechnology sector. Two biotechnology clusters have already been built in Taiwan and the official opening of the National Biotechnology Research Park (NBRP) in Taipei City's Nangang District in 2018, marked an important milestone for the biomedical industry, as it will integrate Taiwan's R&D and start-up incubation capabilities, focusing all the pre-clinical trial activity in a single location.
Biologics World Taiwan provides the FIRST and ONLY platform for senior decision-makers who will influence the future of Taiwan’s biologics industry. Taiwanese and international biopharmas, biotechs, CMOs, CROs, and solution providers will convene to discuss strategic issues, leverage partnerships, share best practices, and capitalize on the potential of Taiwan’s growing biologics industry.
Conference Agenda
Into its 9th edition, Biologics World Taiwan has firmly established itself as Taiwan’s THE biopharmaceutical gathering for new partnerships, ideas, and knowledge. It has doubled its attendee numbers year after year, with 100% of participants judging the conference to be an excellent and beneficial experience. We are proud to continue providing the meeting platform where Taiwan’s growing biopharma industry is at the central stage, receiving more and more global attention on its fast advancement in new biologic drug R&D and biomanufacturing. If you think of these interests, you know more by downloading the brochure!
Registration
2021 Speakers
Chung-Hsiun Wu Development Center of Biotechnology (DCB)
PresidentDevelopment Center of Biotechnology (DCB)Taiwan
Eric C.C. Tang Lukas Biomed Inc.
Chairman and General ManagerLukas Biomed Inc.TaiwanDr. Eric Tang completed his first degree in Business Administration at Carnegie Mellon University, Tepper School of Business. He then attended the School of Medicine and further pursued his postgraduate education at the Institute of Brain Science in National Yang Ming University (NYMU), then returning to basic science research as he realized many unanswered questions in our current knowledge on cancer today.
Dr. Tang joined Galilee Biotech Inc. in 2012, then was appointed as the Chairman of the company in 2015. In the same year, he was also appointed as the General Manager of Lukas Biomedical Inc. He visited Lymphotec Inc. in Japan and served as a researcher in onco-immunology, then completed the training in Japan and successfully transferred the patented technology of Lymphotec to Lukas Biomed Taiwan. After that, he has devoted himself wholeheartedly in the research and development of “Adoptive T Cell Therapy”. Lukas Biomed began its collaboration with Taipei Veterans General Hospital in 2014 and initiated the first T cell clinical trial in combination with chemoradiotherapy for head and neck cancer in Taiwan. In addition, Lukas Biomed managed to obtain Orphan Drug Designation for their T cell products in the use of HCC in US and pre-IND approval was given in 2018. Dr. Tang merged Galilee Biotech and Lukas Biomed in 2018 as part of the new business and research strategy. The new company’s board appointed him as the new Chairman and General Manager of the company to develop a holistic care model for cancer patients. At present, Lukas Biomed Inc. is not only a leading pioneer in T cell immunotherapy research but also the second largest home nursing brand in Taiwan.
Dr. Shugene Lynn United BioPharma (UBP)
Chief Executive OfficerUnited BioPharma (UBP)Taiwan
Dr. Wei Kuang Chi DCB
Vice President DCBTaiwan
Wen Hsiang Chen Baylor College of Medicine
Assistant ProfessorBaylor College of MedicineUSA
Nikolai Petrovsky Vaxine Pvt. Ltd.
Chairman and Research DirectorVaxine Pvt. Ltd.AustraliaNikolai is a Professor of Medicine in the College of Medicine and Public Health at Flinders University and the founder of Vaxine Pvt. Ltd, an Adelaide-based biotechnology company. His research interests including vaccines, adjuvants, and immuno-informatics. He has been principal investigator on multiple large grants from the U.S. National Institutes of Health and has won prestigious awards including the 2010 Ernst & Young Entrepreneur of the Year Award and the 2013 Asian Executive of the Year Award. Last year, he took the first human drug developed by artificial intelligence into human influenza vaccine trials. His current focus is on the development of a vaccine against COVID-19 infection.
Jui-Chen Tsai National Cheng Kung
Professor & Chair, School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical SciencesNational Cheng KungTaiwan Janice Jui-Chen Tsai, Ph.D., is currently Professor and Chair at School of Pharmacy, and Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University (NCKU), Taiwan. She received B.S. in Pharmacy from National Taiwan University in 1978. After graduation, she first worked as a hospital pharmacist, and later transferred to the Bureau of Drugs and Food Analysis, and the Bureau of Drugs, Department of Health, in charge of drug administration. She pursued her graduate training at the University of Michigan and received a Ph.D. degree in Pharmaceutics in 1992. She then decided to go to the University of California, San Francisco and worked under Dr. Peter Elias in Dermatology as a postdoctoral fellow. Dr. Tsai’s affiliation with NCKU started in 1996. Since then, she has been devoted to pharmacy education in Taiwan and was appointed as Director of the Department of Pharmacy in NCKU Hospital. Her research interests include percutaneous absorption, drug delivery systems, skin pharmacokinetics and pharmacodynamics, skin barrier functions, cosmeceuticals, and regulatory aspects of pharmaceutical nanotechnology, in collaboration with dermatology, environmental medicine, TFDA, and pharmaceutical companies. Dr. Tsai published more than 50 papers in scientific journals and more than 80 abstracts in conferences. She also co-authored several book chapters.
Karen Wen Genome Frontier Therapeutics
COO Genome Frontier TherapeuticsTaiwan Karen Wenis a pioneer in the field of biological product development specialized in process development and PIC/S GMP production including peptides, proteins, monoclonal antibodies, DNA vaccine, and antibody-cell conjugate products, and is expanding her professionals in the area of gene and cellular therapy. Karen is the founder and ex-CEO of Mycenax Biotech Inc., the first biological CDMO in Taiwan in 2001~2018. In March 2019, she joined GenomeFrontier Therapeutics Inc. (GF), a startup company as the Chief Operation Officer and Chief Strategy Officer to assist the founder, the technology inventor, to bring her research findings to the clinical phase. GF is the company using the proprietary virus-free system to deliver genes to immune cells for gene and cellular the rapypurposeand qCART™ system is the first system established for CAR-T therapy. This disruptive innovation is expected to provide CAR-T therapy for better efficacy in solid tumor treatment.
This convenience and cost-effectiveness of this virus-free gene manipulation system would lead gene and cellular therapy into a new era. Karen has profound experience in biological products development especially in CMC (chemistry, manufacturing, and control). In her service in Mycenax, 2001~2018, she did follow-on biological product launched and one biosimilar product in global trial and demonstrated bioequivalence in pharmacokinetics and pharmacodynamics. Due to not only the great result in the product quality but also the cost structure, this biosimilar product was successfully out-licensed its European right to a European big pharmaceutical company in 2020. Karen and her team helped several projects getting into the clinical stages, 17 projects in the development, and more than 300 batches of GMP production.
Besides the product development, Karen set up the GMP system of the facility and led this facility as the first one to adopt single-use technology in Asia and the first 2000L, the largest, disposable bioreactor in the world. She also led Mycenax to collaborate with Biosana to pursue the development of full-line continuous manufacturing which was the first one getting into the clinical phase.
With this experience of product development, Karen served as the scientific board member of Academab, a startup company with the entity licensed from Academia Sinica, to guide the company for their pipeline development from 2021. Karen served as the principal investigator and researcher in the Division of Immunology and IVD ProductDevelopment in the Development Center of Biotechnology in 1993~2000. In her term, she successfully developed and commercialized the ELISA kits and rapid test kits in drug residue determination (sulfa drugs, chloramphenicol, beta-agonist)for veterinary and, dairy use, and ELISA and rapid tests for abuse drug residue determination(methamphetamine, morphine, cocaine, marijuana, FM2).
Dr. Steven A. Feldman Stanford Center for Cancer Cell Therapy (CCCT)
DirectorStanford Center for Cancer Cell Therapy (CCCT)
Han-Chung Cheng Founder & Chairman
Founder & ChairmanFounder & ChairmanTaiwan
Yi-Tsau Huang Ministry of Health and Welfare (MOHW)
Director-General, Department of Chinese Medicine and PharmacyMinistry of Health and Welfare (MOHW)Taiwan
Kevin Ho Steminent Biotherapeutics
Director of Clinical DepartmentSteminent BiotherapeuticsTaiwan
Cyrus Yang TaiwanBio Therapeutics
COOTaiwanBio TherapeuticsTaiwan
Chien-Tsun Kuan ARCE Therapeutics Inc.,
CEO & Co-FounderARCE Therapeutics Inc.,Taiwan
John Lin Hualien Tzu Chi Hospital
Superintendent Hualien Tzu Chi HospitalTaiwan
Ye-Su Chao GNTbm
Vice-PresidentGNTbmTaiwan
Lily Lien TOT Biopharm
Project DirectorTOT BiopharmChina
Ignacio Asial DotBio
CEO & FounderDotBioSingapore
Dr. Lih-Jiuan Hsu Center for Drug Evaluation (CDE)
Deputy Executive DirectorCenter for Drug Evaluation (CDE)Taiwan
Pei-Jiun Chen Mycenax Biotech Inc.
CEO & PresidentMycenax Biotech Inc.Taiwan
Ping-Yang Yeh EirGenix
Vice President & CYOEirGenixTaiwan Dr. Yeh spent 24 years in the biopharmaceutical and pharmaceutical industry in the US after obtaining his doctoral degree. Prior to returning to Taiwan to join EirGenix, Dr. Yeh was Executive Director in Process Development, Amgen (2011-2019). Prior to Amgen, Dr. Yeh held increased responsibility in managerial and technical leadership in Biogen Idec (2006-2011) and GlaxoSmithKline/SmithKline Beecham (1995-2006).
During his tenure in the US, Dr. Yeh has engaged and involved with the development of a diverse set of therapeutic modalities (both biologics and synthetics) in molecular design, process and product development and manufacturing, including product life cycle management. He has contributed to the successful launch of 17 commercial products and 45 IND/INDa filings.
Dr. Yeh received his Ph.D. in Pharmaceutics and Pharmaceutical Chemistry under Professor Jindrich Henry Kopecek, and M.S. in Material Sciences and Engineering under Professor Joseph Andrade, both from The University of Utah. He received his B.S. degree in Chemical Engineering from Tamkang University in Taiwan.
Dr. Xiao Pan GenScript ProBio
Director of Process R&DGenScript ProBioXiao Pan is Director of Process R&D at GenScript ProBio. Prior to this Dr. Pan was a Principal Scientist at Fujifilm Diosynth, UK and also worked at Synthon, Netherlands as an Upstream Process Development scientist. He has a PhD degree from Wageningen University, Netherlands.
Yuen-Fen Tan Lukas Biomedical Inc.,
Country DirectorLukas Biomedical Inc., Malaysia
Terence Lee West Pharmaceutical Services
Senior Technical Account Specialist West Pharmaceutical Services
Julio Lin Blue Blood Biotech Corp
Vice PresidentBlue Blood Biotech CorpTaiwanDr. Lin is a biomedical scientist with over 20 years of commercial process in life science industries, including medical devices, pharmaceutical, biomaterials manipulate technology and biochips.
Prior to joining Blue Blood Biotech Corp., Dr. Lin was the Deputy Project Director of Industrial Technology Research Institute (ITRI), which is a biggest R&D organization in Taiwan engaging in applied research and technical services.
He was responsible for global cooperation in integrates from small to big key account’s company to form a complete strategic alliance. He was Senior VP at Body Organ Biomedical Inc (listed company in Taiwan Stock Exchange Market) with cross continental’s office, covering TWN, China and the Netherlands.
During his around 10 years tenure at BOBC, which proceeded rapidly co-built sales organization operation at the Netherlands including related regulation approval.
He was not only build efficiency way to synergistic clinical trials and marketing tools, but also broadens the sales channels by shifting the company’s focus from ophthalmology oriented to biomaterials.
As a headquarter based in Taiwan, he lead the team to get first grant of SenterNovem from Ministry of Economic Affairs of the Netherlands for 0.3 million Euro with leading multinational research teams of China, Taiwan and the Netherlands in 2009!
He had successfully filing 36 patents with cost effective strategy of joint research in ProTop Mediking Biomedical Inc. In 2000, he initiated and ready for registration of class II medical device in Purzer pharmaceutical company, this is the first bone filler registration in Taiwan.
Dr. Lin was not only earned his Ph.D. from the Institute of Bioengineering in National Taiwan University but also expand his training to business by get a MBA degree from National Chen Chi University.
Sponsors & Exhibitors
GOLD SPONSOR
SILVER SPONSOR
ASSOCIATE SPONSOR
TECHNOLOGY SHOWCASE SPONSOR
EXHIBITOR
ADVERTISER
SUPPORTER
Become A Sponsor!
Be part of the ONLY biologics and biosimilars focused platform in Taiwan!
Your business is much more than just knocking on doors. Your marketing strategy is much more than a leads generator. To generate sales, you need brand credibility and a good leadership position. To create awareness and response, you need a targeted and motivated audience who are leaders in both local and international biologics industries that are capable of putting pen to paper. To generate profits, come and embark on the marketing and business development services of Biologics World Taiwan 2020!
Sales and Marketing Opportunities at Biologics World Taiwan!
Biologics World Taiwan is the ONLY event in Taiwan for senior decision-makers who will influence the future of Taiwan’s biologics industry. Leverage on this year’s best marketing and sales opportunity to access the fastest growing biologics market of the world! Be there and be seen!
Market Intelligence
English 
简体中文 
日本語 
한국어 
繁體中文